About this Abstract |
Meeting |
2024 TMS Annual Meeting & Exhibition
|
Symposium
|
Materials Science for Global Development -- Health, Energy, and Environment: An SMD Symposium in Honor of Wole Soboyejo
|
Presentation Title |
PLGA-PEG Microparticles for Targeted Drug Delivery in the Treatment of Triple Negative Breast Cancer Cells. |
Author(s) |
Sandra M. Borbor-Sawyer, John David Obayemi, Ali Azeko Salifu, Clare Chukwudalu Nwazojie, Vanessa Obiageli Uzonwanne, Olushola Segun Odusanya, Winston Oluwole Soboyejo |
On-Site Speaker (Planned) |
Sandra M. Borbor-Sawyer |
Abstract Scope |
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and has poorer prognosis and clinical outcomes compared to other types of breast cancer. TNBC lacks the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor 2 (HER2). This causes TNBC to be non-responsive to endocrine/anti-HER 2 therapies designed to target those receptors. Conventional treatment methods are ineffective in treating TNBC because they are non-targeted and require high drug concentrations thereby causing harmful side effects. To improve outcomes, it is essential to develop drug delivery systems that target TNBC. We developed targeted drug systems to treat and prevent locally recurring TNBC tumors after surgical resection. The in vitro drug release was done at three temperatures to study the kinetics and thermodynamics of drug release. Our results revealed that LHRH-conjugated drugs greatly reduced TNBC’s cell viability and prevented its loco-regional recurrence in vitro and in vivo. |
Proceedings Inclusion? |
Planned: |
Keywords |
Biomaterials, Other, Other |